



## Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th

Feb 27, 2018

REDWOOD CITY, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018. At 4:30 p.m. Eastern Time, Coherus' management will host a conference call to discuss the financial results and provide a general business update.

After releasing fourth quarter and full year 2017 financial results, we will post them on the Coherus BioSciences website at <http://investors.coherus.com>.

### Conference Call Information

When: Thursday, March 8, 2018 at 4:30 p.m. ET

Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)

Conference ID: 7098068

Webcast: <http://investors.coherus.com>

Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.

### About Coherus BioSciences, Inc.

Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit [www.coherus.com](http://www.coherus.com).

### CONTACT:

Patrick O'Brien

Senior Vice President, Investor Relations

Coherus BioSciences, Inc.

[pobrien@coherus.com](mailto:pobrien@coherus.com)

+1 (650) 649-3527



Coherus BioSciences, Inc.